Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer

Thoracic Cancer

Volumn 4, Issue 4, 2013, Pages 440-448

  Sun, Yan ^a   Wang, Jin Wan ^a   Liu, Yong Yu ^b   Yu, Qi Tao ^c   Zhang, Yi Ping ^d   Li, Kai ^e   Xu, Li Yan ^f   Luo, Su Xia ^g   Qin, Feng Zhan ^h   Chen, Zheng Tang ⁱ   Liu, Wen Chao ^j   Zhou, Qing Hua ^k   Chen, Qiang ^l   Nan, Ke Jun ^m   Liu, Xiao Qing ⁿ   Liu, Wei ^o   Liang, Hou Jie ⁱ   Lu, Hui Shan ^l   Wang, Xiu Wen ^p   Wang, Jie Jun ^q   Song, Shu Ping ^r   Tu, Yuan Rong ^l   Zhou, Jing Min ^s   Li, Wei Lian ^t   Yao, Chen ^u   more..

^a CANCER HOSPITAL   (China)

^b Liaoning Provincial Cancer Hospital   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d Zhejiang Provincial Cancer Hospital   (China)

^e KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g Henan Provincial Cancer Hospital   (China)

^h Anhai Provincial Cancer Hospital   (China)

ⁱ CHONGQING MEDICAL UNIVERSITY   (China)

^j FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^k SICHUAN UNIVERSITY   (China)

^l FUJIAN MEDICAL UNIVERSITY   (China)

^m Xian Communication University   (China)

ⁿ Beijing 307 Hospital   (China)

^o Hebei Provincial Hospital   (China)

^p SHANDONG UNIVERSITY   (China)

^q SECOND MILITARY MEDICAL UNIVERSITY   (China)

^r SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^s Tianjin Chest Hospital   (China)

^t TIANJIN HOSPITAL   (China)

^u PEKING UNIVERSITY FIRST HOSPITAL   (China)

more..

Author keywords

Advanced and relapsed NSCLC; Angiogenesis inhibitor; Endostar; NP regimen; Recombinant human endostatin; Survival benefit

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; NAVELBINE; PLACEBO; RECOMBINANT ENDOSTATIN;

ACUTE ABDOMEN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84887011876     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12050     Document Type: Article

References (56)

1. Houwen L. State of the art: lung cancer in China. Ann Thorac Cardiovasc Surg 2003; 9: 147-148.
2. Yao M. Death caused by lung cancer soars in China. 2008-04-29. [Cited 27 May 2013 Available from URL: http://news.xinhuanet.com/english/2008-04/29/content_8074947.htm
3. Parkin DM, Whelan SL, Ferlay WJ, Storm HH, eds. Cancer Incidence in Five Continents, Vol. 1-8, No. 7. IARC Cancer Base, Lyon 2005.
4. Scagliotti GV, De Marinis F, Rinaldi M etal. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
5. Le Chevalier T, Brisgand D, Douillard JY etal. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncal 1994; 12: 360-367.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
7. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
8. Herblin WF, Gross JL. Inhibition of angiogenesis as a strategy for tumor growth control. Mol Chem Neuropathol 1994; 21: 329-336.
9. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
10. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225.
11. Westphal JR, Van't Hullenaar R, Peek R etal. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000; 86: 768-776.
12. O'Reilly MS, Holmgren L, Shing Y etal. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
13. O'Reilly MS, Boehm T, Shing Y etal. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
14. Maeshima Y, Yerramalla UL, Dhanabal M etal. Extracellular matrix-derived peptide binds to alpha (v)beta (3) integrin and inhibits angiogenesis. J Biol Chem 2001; 276: 31959-31968.
15. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
16. Ling Y, Yang Y, Lu N etal. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007; 361: 79-84.
17. Lu N, Ling Y, Gao Y etal. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med 2008; 233: 1013-1020.
18. Ling Y, Lu N, Gao Y etal. Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res 2009; 29: 411-417.
19. Yang L, Wang JW, Tang ZM etal. A phase I clinical trial for recombinant human endostatin. Chin J New Drugs 2004; 13: 548-553.
20. Yang L, Wang JW, Cui CX etal. Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Chin J New Drugs 2005; 14: 204-207.
21. Sun Y, Wang JW, Liu Y etal. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small lung cancer (NSCLC) patients. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl.): Abstract 7138.
22. Wang JW, Sun Y, Liu YU. [Results of randomized, multicenter double-blind phase III trial of rh-endostatin (YH-16) in advanced non-small lung cancer (NSCLC) patients.] Chin J Lung Cancer 2005; 8: 283-290 (In Chinese).
23. Gebbia V, Galetta D, Caruso M etal. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003; 39: 179-189.
24. Hurwitz H, Fehrenbacher L, Novotny W etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
25. Miller KD, Wang W, Gralow J etal. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94 (Suppl. 1): S6; abstract.
26. Sandler A, Gray R, Perry MC etal. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
27. Shepherd FA. Second-line chemotherapy for non-small-cell lung cancer. Expert Rev Anticancer Ther 2003; 3: 435-442.
28. Schiller JH, Harrington D, Belani CP etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
29. Fossella F, Pereira JR, von Pawel J etal. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
30. Belani CP, Brodowicz T, Ciuleanu T etal. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). 2009 ASCO Annual Meeting Proceedings J Clin Oncol 2009; 27 (Suppl.): 15s; Abstract CRA8000.
31. Kim H, Hirsh V, Mok T etal. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-1818.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
33. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970-1995. Chest 1998; 113: 467-481.
34. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001; 12: 1667-1670.
35. Han BH, Xiu QY, Wang HM etal. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with Endostar for advanced non-small cell lung cancer (NSCLC).] Chin J Oncol 2011; 33: 854-859. (In Chinese.)
36. Gu M, Geng LM, Sun HW. [Clinical study of recombininant human endostatin with GP regimen in the treatment of advanced non-small cell lung cancer.] Cancer Res Clin 2011; 23: 690-692. (In Chinese.)
37. Yang RX, Ren HX, Zhong L etal. [Clinical study of the rh-endostatin combined with TP regimen for advanced non-small cell lung cancer.] Chin Clin Oncol 2010; 15: 453-456. (In Chinese.)
38. Duan HQ, Wang YY, Zhou M. [Clinical observation of Endostar combined with pemetrexed for advanced non-small cell lung cancer.] Chin Clin Oncol 2010; 15: 160-162. (In Chinese.)
39. Yuan J, Wu CW, Liu ZJ Wei XY, Li K. [Observation of the antitumor effect of Endostar combined with docetaxel under different administration sequences.] Chin J Oncol 2010; 32: 580-585.] (In Chinese.)
40. Zhao X, Cai XH, Zhou CY etal. [Clinical study of Endostar combined with FOLFOLX as a second line chemotherapy for advanced colorectal cancer.] Cancer Res Clin 2009; 21: 830-832. (In Chinese.)
41. Pan HX, Ren G, Deng CM etal. [Efficacy of Endostar and FOLFOX 4 in advanced cikirectak carcinoma.] Chin Clin Oncol 2010; 15: 655-657. (In Chinese.)
42. Guo YB, Deng L, Zhu WR etal. [Clinical observation of rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer.] Chin J Oncol 2011; 16: 742-745. (In Chinese.)
43. Lu XL, Zuo Y, Xu S etal. [Endostar combined with chemotherapy in 28 patients with advanced gastrointestinal system cancer.] Chin Clin Oncol 2010; 15: 78-81. (In Chinese.)
44. Xu HX, Huang XE, Qian ZY etal. [Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients.] Asian Pac J Cancer Prev 2011; 12: 3087-3090. (In Chinese.)
45. Jiang ZY, Qin SK. [Study progression of recombinant human endostatin (Endostar) for the treatment of malignant cavity effusion.] Chin Clin Oncol 2010; 15: 937-943. (In Chinese.)
46. Gao WB, Wang WL, Wang RY etal. [Clinical observation of Endostar in the treatment of malignant serous cavity effusions.] Chin Clin Oncol 2009; 14: 544-546. (In Chinese.)
47. Zuo L, Tao L, Li G etal. [Endostar combined with cisplatin in the treatment for malignant effusion and ascites and their impact on vascular endothelial grow factor.] J Chin Oncol 2012; 18: 875-878. (In Chinese.)
48. Leu XF, Qin SK, Wang L etal. [Clinical study of Endostar on malignant cavity effusion.] Chin Clin Oncol 2011; 16: 800-894. (In Chinese.)
49. He BF, Zhang LS, Luo RC. [The inhibitory effect of recombinant human endostatin on the growth of human esophageal carcinoma cell.] Chin Clin Oncol 2010; 15: 605-607. (In Chinese.)
50. Shen WX, Zhao Y, Yan Y etal. [Endostar and peclitaxel combination induced apoptosis in breast cancer cells with Her-2 over-expression.] J Chin Oncol 2012; 18: 844-847. (In Chinese.)
51. Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, Zhen YS Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett 2011; 301: 212-220.
52. Ke QH, Zhou SQ, Huang M, Lei Y, Du W, Yang JY. Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev 2012; 13: 923-926.
53. Shi HB, Huang YJ, Zhou H etal. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of Endostatin. Blood 2007; 110: 2899-2906.
54. Folkman J. Endostatin finds a new partner: nucleolin. Blood 2007; 110: 2786-2787.
55. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
56. Tsao MS, Sakurada A, Cutz JC etal. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353 133-144.